Sjögren-Larsson syndrome: Diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2)

William B Rizzo, Gael Carney

Research output: Contribution to journalReview article

88 Citations (Scopus)

Abstract

Sjögren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, and spastic diplegia or tetraplegia. The disease is caused by mutations in the ALDH3A2 gene (also known as FALDH and ALDH10) on chromosome 17p11.2 that encodes fatty aldehyde dehydrogenase (FALDH), an enzyme that catalyzes the oxidation of long-chain aldehydes derived from lipid metabolism. In SLS patients, 72 mutations have been identified, with a distribution that is scattered throughout the ALDH3A2 gene. Most mutations are private but several common mutations have been detected, which probably reflect founder effects or recurrent mutational events. Missense mutations comprise the most abundant class (38%) and expression studies indicate that most of these result in a profound reduction in enzyme activity. Deletions account for about 25% of the mutations and range from single nucleotides to entire exons. Twelve splice-site mutations have been demonstrated to cause aberrant splicing in cultured fibroblasts. To date, more than a dozen intragenic ALDH3A2 polymorphisms consisting of SNPs and one microsatellite marker have been characterized, although none of them alter the FALDH protein sequence. The striking mutational diversity in SLS offers a challenge for DNA-based diagnosis, but promises to provide a wealth of information about enzyme structure-function correlations.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalHuman mutation
Volume26
Issue number1
DOIs
StatePublished - Jul 1 2005

Fingerprint

long-chain-aldehyde dehydrogenase
Mutation
Genes
Enzymes
Founder Effect
Ichthyosis
Quadriplegia
Missense Mutation
Cerebral Palsy
Lipid Metabolism
Aldehydes
Intellectual Disability
Microsatellite Repeats
Single Nucleotide Polymorphism
Exons
Nucleotides
Fibroblasts
Chromosomes

Keywords

  • ALDH3A2
  • Aldehyde dehydrogenase
  • Fatty alcohol
  • Fatty-aldehyde
  • Ichthyosis
  • Mental retardation
  • SLS
  • Spasticity

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Sjögren-Larsson syndrome : Diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2). / Rizzo, William B; Carney, Gael.

In: Human mutation, Vol. 26, No. 1, 01.07.2005, p. 1-10.

Research output: Contribution to journalReview article

@article{b216d84c913c42b4a319b3cc214afe14,
title = "Sj{\"o}gren-Larsson syndrome: Diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2)",
abstract = "Sj{\"o}gren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, and spastic diplegia or tetraplegia. The disease is caused by mutations in the ALDH3A2 gene (also known as FALDH and ALDH10) on chromosome 17p11.2 that encodes fatty aldehyde dehydrogenase (FALDH), an enzyme that catalyzes the oxidation of long-chain aldehydes derived from lipid metabolism. In SLS patients, 72 mutations have been identified, with a distribution that is scattered throughout the ALDH3A2 gene. Most mutations are private but several common mutations have been detected, which probably reflect founder effects or recurrent mutational events. Missense mutations comprise the most abundant class (38{\%}) and expression studies indicate that most of these result in a profound reduction in enzyme activity. Deletions account for about 25{\%} of the mutations and range from single nucleotides to entire exons. Twelve splice-site mutations have been demonstrated to cause aberrant splicing in cultured fibroblasts. To date, more than a dozen intragenic ALDH3A2 polymorphisms consisting of SNPs and one microsatellite marker have been characterized, although none of them alter the FALDH protein sequence. The striking mutational diversity in SLS offers a challenge for DNA-based diagnosis, but promises to provide a wealth of information about enzyme structure-function correlations.",
keywords = "ALDH3A2, Aldehyde dehydrogenase, Fatty alcohol, Fatty-aldehyde, Ichthyosis, Mental retardation, SLS, Spasticity",
author = "Rizzo, {William B} and Gael Carney",
year = "2005",
month = "7",
day = "1",
doi = "10.1002/humu.20181",
language = "English (US)",
volume = "26",
pages = "1--10",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Sjögren-Larsson syndrome

T2 - Diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2)

AU - Rizzo, William B

AU - Carney, Gael

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Sjögren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, and spastic diplegia or tetraplegia. The disease is caused by mutations in the ALDH3A2 gene (also known as FALDH and ALDH10) on chromosome 17p11.2 that encodes fatty aldehyde dehydrogenase (FALDH), an enzyme that catalyzes the oxidation of long-chain aldehydes derived from lipid metabolism. In SLS patients, 72 mutations have been identified, with a distribution that is scattered throughout the ALDH3A2 gene. Most mutations are private but several common mutations have been detected, which probably reflect founder effects or recurrent mutational events. Missense mutations comprise the most abundant class (38%) and expression studies indicate that most of these result in a profound reduction in enzyme activity. Deletions account for about 25% of the mutations and range from single nucleotides to entire exons. Twelve splice-site mutations have been demonstrated to cause aberrant splicing in cultured fibroblasts. To date, more than a dozen intragenic ALDH3A2 polymorphisms consisting of SNPs and one microsatellite marker have been characterized, although none of them alter the FALDH protein sequence. The striking mutational diversity in SLS offers a challenge for DNA-based diagnosis, but promises to provide a wealth of information about enzyme structure-function correlations.

AB - Sjögren-Larsson syndrome (SLS) is an autosomal recessive disorder characterized by ichthyosis, mental retardation, and spastic diplegia or tetraplegia. The disease is caused by mutations in the ALDH3A2 gene (also known as FALDH and ALDH10) on chromosome 17p11.2 that encodes fatty aldehyde dehydrogenase (FALDH), an enzyme that catalyzes the oxidation of long-chain aldehydes derived from lipid metabolism. In SLS patients, 72 mutations have been identified, with a distribution that is scattered throughout the ALDH3A2 gene. Most mutations are private but several common mutations have been detected, which probably reflect founder effects or recurrent mutational events. Missense mutations comprise the most abundant class (38%) and expression studies indicate that most of these result in a profound reduction in enzyme activity. Deletions account for about 25% of the mutations and range from single nucleotides to entire exons. Twelve splice-site mutations have been demonstrated to cause aberrant splicing in cultured fibroblasts. To date, more than a dozen intragenic ALDH3A2 polymorphisms consisting of SNPs and one microsatellite marker have been characterized, although none of them alter the FALDH protein sequence. The striking mutational diversity in SLS offers a challenge for DNA-based diagnosis, but promises to provide a wealth of information about enzyme structure-function correlations.

KW - ALDH3A2

KW - Aldehyde dehydrogenase

KW - Fatty alcohol

KW - Fatty-aldehyde

KW - Ichthyosis

KW - Mental retardation

KW - SLS

KW - Spasticity

UR - http://www.scopus.com/inward/record.url?scp=22144493352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144493352&partnerID=8YFLogxK

U2 - 10.1002/humu.20181

DO - 10.1002/humu.20181

M3 - Review article

C2 - 15931689

AN - SCOPUS:22144493352

VL - 26

SP - 1

EP - 10

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 1

ER -